{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:19:22Z","timestamp":1787689162949,"version":"build-2784847793"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,25]]},"DOI":"10.7759\/cureus.115170","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:24:15Z","timestamp":1787685855000},"source":"Crossref","is-referenced-by-count":0,"title":["Implicit Rationing of Incretin Therapy in Diabetic Kidney Disease: A Call for Deliberate Allocation"],"prefix":"10.7759","author":[{"given":"Diego","family":"de Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achille","family":"Peiris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic V","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al.. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024, 391:109-21. 10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024, 105:S117-314. 10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7326\/M21-2941","article-title":"First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness study","volume":"175","author":"Choi JG","year":"2022","unstructured":"Choi JG, Winn AN, Skandari MR, et al.. First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness study. Ann Intern Med. 2022, 175:1392-400. 10.7326\/M21-2941","journal-title":"Ann Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05832-0","article-title":"Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis","volume":"66","author":"Morton JI","year":"2023","unstructured":"Morton JI, Marquina C, Shaw JE, Liew D, Polkinghorne KR, Ademi Z, Magliano DJ. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis. Diabetologia. 2023, 66:642-56. 10.1007\/s00125-022-05832-0","journal-title":"Diabetologia"},{"key":"ref5","unstructured":"US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. (2025). Accessed: July 12, 2026: https:\/\/www.fda.gov\/drugs\/drug-alerts-and-statements\/fda-clarifies-policies-compounders-national-glp-1-supply-begins-...."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/525797-implicit-rationing-of-incretin-therapy-in-diabetic-kidney-disease-a-call-for-deliberate-allocation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:24:16Z","timestamp":1787685856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/525797-implicit-rationing-of-incretin-therapy-in-diabetic-kidney-disease-a-call-for-deliberate-allocation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":5,"URL":"https:\/\/doi.org\/10.7759\/cureus.115170","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,25]]}}}